Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zirdafulven · LP-184, LP-284

Small molecule · Cytotoxic, directed at DNA (N3-adenine) · developed by Lantern Pharma

Phase 1/2 Most advanced trial
LTRN Developer
2 Registered trials

What is Zirdafulven?

Zirdafulven (LP-184) is a tumor-site activated acylfulvene-derived prodrug that is converted by prostaglandin reductase 1 (PTGR1), an enzyme elevated in certain tumors. The active form alkylates DNA at N3-adenine, causing double-strand breaks that tumor cells with DNA damage repair deficiencies cannot repair. It is studied in solid tumors, triple-negative breast cancer, glioblastoma, non-small cell lung cancer, pancreatic adenocarcinoma and relapsed or refractory lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LP-184, LP-284
Drug type
Small molecule
Targets
DNA (N3-adenine), prostaglandin reductase 1 (PTGR1) (biomarker)
Mechanism
Cytotoxic, directed at DNA (N3-adenine)
Pathways
DNA damage repair, apoptosis
Therapy area
Oncology
Developer
Lantern Pharma Inc. (LTRN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
L683VC69K8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05933265 Phase 1/2 Advanced Solid Tumor Active not recruiting LTRN
NCT06132503 Phase 1 Relapsed or Refractory Lymphomas Recruiting LTRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorDDR Gene MutationGBMMetastatic Solid TumorNSCLCPancreatic AdenocarcinomaRelapsed or Refractory LymphomasTNBC - Triple-Negative Breast Cancer

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LTRN page.

Follow LTRN, the company behind Zirdafulven

See LTRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LTRN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.